PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO CEO & Investor Conference at 8:00 a.m. Eastern time on Monday, February 14, 2011, at the Waldorf-Astoria Hotel in New York City, New York. Dr. Anzalone will be discussing recent Company developments and its opportunities in nanomedicine.
The presentation will be webcast live and can be accessed by visiting the Company's website at www.arrowheadresearch.com. A replay of the presentation will be archived on the Arrowhead website for 90 days.
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference is a must-attend event for institutional investors, industry analysts, and senior biotechnology executives focused on shaping the future investment landscape of the biotechnology industry. For more information on the conference, visit http://www.bio.org/bioceo.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit http://www.arrowheadresearch.com.
Investor Relations Contact:
The Piacente Group, Inc.
Brandi Floberg, 212-481-2050
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Technology Nanotechnology Health Biotechnology Genetics Pharmaceutical Manufacturing Engineering Professional Services Finance